No abstract available.
Chemotherapy, Adjuvant ; Colorectal Neoplasms ; Humans

No abstract available.
Chemotherapy, Adjuvant ; Uterine Cervical Neoplasms

Dysgerminoma comprises 3%–5% among ovarian malignancies, mostly seen in adolescent and early adult women. The recurrence rate is approximately 10%–20%, occurring within 2 years of diagnosis, and has been reported that more than 75% occur in the 1st year. A 19‑year‑old nulligravid initially presented with severe abdominal pain, who underwent emergency exploratory laparotomy and left salpingo‑oophorectomy, whose histopathologic result revealed dysgerminoma, Stage IC2. Recurrence of dysgerminoma was noted on the contralateral ovary 10 months after for which she had undergone another surgery for wedge resection of the right ovarian mass and complete surgical staging. She received adjuvant chemotherapy without complications. Despite two consecutive surgeries and chemotherapy, she had conceived naturally and her pregnancy was carried to term with no complications and delivered to a live baby girl by normal spontaneous delivery. This case is a proof of how fertility‑sparing surgeries and chemotherapy in dysgerminoma can successfully preserve reproductive functions for future conceptions.
Chemotherapy, Adjuvant ; Dysgerminoma ; Pregnancy ; Recurrence

BACKGROUND

Studies reported survival benefits from early initiation of adjuvant chemotherapy from the time of mastectomy among breast cancer patients.

The researchers aimed to determine if early initiation of adjuvant chemotherapy among early-stage breast cancer patients undergoing modified radical mastectomy at Bataan General Hospital and Medical Center has increased the patient’s survival. We also want to asses if the Bataan General Hospital and Medical Center department of Oncology is rendering adjuvant chemotherapy as compared to the international standards. We also want to know the factors affecting the timing of initiation of adjuvant chemotherapy among the subjects.

A retrospective cohort study involving chart review covering the year May 2015 to January 2020 for stage 1 to 3 breast cancer patients, with a histopathologic confirmation, underwent definitive/curative breast surgery, and had started on adjuvant cytotoxic chemotherapy are included in the study.

In this retrospective study, we observed that time to initiation of adjuvant chemotherapy among breast cancer patients at Bataan General Hospital and Medical Center does not significantly improve overall survival of patients. The BGHMC Department of Oncology service is trailing the cut off 12 weeks or 84 days of initiation of adjuvant chemotherapy from the date of mastectomy. We also used the factors that affects the timing of initiation of adjuvant chemotherapy and found out that these variables cannot predict whether it will increase the patient’s survival since our sample size is too small.

PURPOSE: The purpose of this study is to assess the role of adjuvant therapy in stage I-III gallbladder cancer (GBC) patients who have undergone R0 resection. MATERIALS AND METHODS: Clinical data were collected on 441 consecutive patients who underwent R0 resection for stage I-III GBC. Eligible patients were classified into adjuvant therapy and surveillance only groups. Propensity score matching (PSM) between the two groups was performed, adjusting clinical factors. RESULTS: In total, 84 and 279 patients treated with adjuvant therapy and followed up with surveillance only, respectively, were included in the analysis. Before PSM, the 5-year relapse-free survival (RFS) rate was lower in the adjuvant therapy group than in the surveillance only group (50.8% vs. 74.8%, p < 0.001), although there was no statistically significant difference in the 5-year overall survival (OS) rate (66.2% vs. 79.5%, p=0.089). After the PSM, baseline characteristics became comparable and there were no differences in the 5-year RFS (50.8% vs. 64.8%, p=0.319) and OS (66.2% vs. 70.4%, p=0.703) rates between the two groups. CONCLUSION: The results suggest that fluoropyrimidine-based adjuvant therapy is not indicated in stage I-III GBC patients who have undergone R0 resection.
Chemoradiotherapy, Adjuvant ; Chemotherapy, Adjuvant ; Gallbladder Neoplasms* ; Gallbladder* ; Humans ; Propensity Score

PURPOSE: Dukes' A & B colorectal cancer patients are often excluded from adjuvant chemotherapy following potentially curative surgery because they are expected to have good long-term survival. However, actually 20 ~ 30% of these patients suffer from recurrent disease, so it would be helpful for these patients of recurrent disease to be able to select a high risk group. METHODS: In 78 Dukes' A & B colorectal cancers, we investigated by immunohistochemistry the role of molecular markers, such as p27(kip1), p53, Ki-67, and Skp2, in identifying high-risk patients. RESULTS: Patients with low p27(kip1) expression showed poor overall survival compared to those with high p27(kip1) expressions (55.3 versus 66.7 months, P=0.018). The only significant factor associated with p27(kip1) expression was p53 expression. The low p27(kip1) expression and positive p53 expression group had poor overall survival (54.3 months, P=0.036). CONCLISIONS: In a node-negative colorectal carcinoma, the molecular marker p27(kip1) does not play an independent prognostic role, but it may have prognostic significance in correlation with other markers such as p53, Ki-67, and Skp2. The assessment of molecular alterations may be useful to node-negative colorectal patients in identifying the high risk group that may benefit from adjuvant chemotherapy.
Chemotherapy, Adjuvant ; Colorectal Neoplasms* ; Humans ; Immunohistochemistry ; Prognosis

Malignant mesothelioma of the uterus is a rare mesenchymal neoplasm originating from the mesothelial surface cell lining of the uterus. It is known to have very poor prognosis with median survival period of 4-18 months. We report a rare case of primary malignant mesothelioma of the uterus showing no evidence of recurrence for 2 years, after management with operation and adjuvant chemotherapy.
Chemotherapy, Adjuvant ; Mesothelioma* ; Peritoneum ; Prognosis ; Recurrence ; Uterus*

Malignant mesothelioma of the uterus is a rare mesenchymal neoplasm originating from the mesothelial surface cell lining of the uterus. It is known to have very poor prognosis with median survival period of 4-18 months. We report a rare case of primary malignant mesothelioma of the uterus showing no evidence of recurrence for 2 years, after management with operation and adjuvant chemotherapy.
Chemotherapy, Adjuvant ; Mesothelioma* ; Peritoneum ; Prognosis ; Recurrence ; Uterus*

Desmoplastic cerebral astrocytoma of infancy is a rare neoplasm with distinctive clinical and radiographicfeatures. Almost all cases present in the first two years of life as a large, supratentorial, enhancing mass witha peripheral dural-based solid component and a central cystic component. After complete surgical excision, thecourse of this tumor is benign, and adjuvant chemotherapy or radiation therapy may not be required. We describethe case of a 9-month-old boy with a desmoplastic cerebral astrocytoma of infancy and review the associatedliterature.
Astrocytoma* ; Chemotherapy, Adjuvant ; Humans ; Infant ; Male

No abstract available.
Chemotherapy, Adjuvant* ; Colonic Neoplasms* ; Humans ; Prognosis*